Long-term outcome for immune suppression and immune related lymphoproliferative disorder: Prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004

Taj, Mary M., Hadzic, Nedim, Height, Susan E., Wotherspoon, Andrew, Burke, Margaret, Hobson, Rachel, Viskaduraki, Maria and Pinkerton, C. Ross (2012) Long-term outcome for immune suppression and immune related lymphoproliferative disorder: Prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004. Leukemia and Lymphoma, 53 5: 842-848. doi:10.3109/10428194.2011.634045


Author Taj, Mary M.
Hadzic, Nedim
Height, Susan E.
Wotherspoon, Andrew
Burke, Margaret
Hobson, Rachel
Viskaduraki, Maria
Pinkerton, C. Ross
Title Long-term outcome for immune suppression and immune related lymphoproliferative disorder: Prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004
Journal name Leukemia and Lymphoma   Check publisher's open access policy
ISSN 1042-8194
1029-2403
Publication date 2012-01-01
Year available 2011
Sub-type Article (original research)
DOI 10.3109/10428194.2011.634045
Open Access Status Not yet assessed
Volume 53
Issue 5
Start page 842
End page 848
Total pages 7
Place of publication Abingdon, Oxfordshire, United Kingdom
Publisher Taylor & Francis
Language eng
Abstract Prospective national registry data on 98 patients were studied to determine the long-term outcome of immune related lymphoproliferative disease (LPD) and define prognostic factors. Seventy-three developed LPD following organ transplant (26 liver, 21 heart, 15 kidney, nine bone marrow [BM], two bowel). Twenty-five had non-transplant related immunosuppression. Age was 1.1-17 years (median 8.6). Fifty-eight patients had lymphomatous, 21 systemic and 17 lymphadenopathic disease. Sixty (73%) were disseminated and 22 (27%) localized. Thirty-three (54%) were monoclonal. Seventy-three (83%) were EpsteinBarr virus (EBV) positive. Median follow-up was 7.6 years. LPD developed earlier after liver and BM as compared to heart or kidney transplant. Five-year overall survival (OS) was 58%. Prognosis was best after liver and kidney transplant (OS >77%). Mortality was higher following heart (2.5 times) and BM transplant (5 times). Adverse prognostic factors were disseminated or lymphomatous disease and lack of reduction of immunosuppression. With appropriate reduction of immunosuppression, rituximab and low-dose chemotherapy, long-term survival is high.
Keyword Chemotherapeutic approaches
Lymphoma and Hodgkin disease
Prognostication
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 09 Jul 2016, 04:23:37 EST by System User on behalf of Learning and Research Services (UQ Library)